Sanofi S.A., FR0000120578

Sanofi expands Regeneron alliance as Sanofi stock falls 3.16 percent

Published on 10/02/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal adds four antibodies and includes USD 1.0 billion upfront. Sanofi stock costs EUR 70.23 on October 2, 2026 after EUR 72.52.

Architectural visualization render of a futuristic pharmaceutical laboratory building with cleanroom airlocks, floor-to-ceiling glass walls and violet-blue accent lighting — Sanofi FR0000120578 architectural CGI render of multi-story high-tech pharmaceutical laboratory with cleanroom airlock entry, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 70.23 at Lang & Schwarz on October 2, 2026 at 12:31 p.m. CEST, down 3.16 percent versus the prior close of EUR 72.52. On October 1, 2026, Sanofi and Regeneron expanded their antibody alliance to develop four next-generation, long-acting immunology medicines, a move Reuters described as an early test of CEO Belén Garijo's strategy.

Four antibodies reshape the pipeline

According to Sanofi on October 1, 2026, the expanded collaboration adds antibodies targeting interleukin-13, interleukin-4, an IL-4xIL-13 bispecific and interleukin-4 receptor alpha. The lead asset, REGN20423, is in a phase 1 study for atopic dermatitis, while the other three programs are expected to enter clinical studies in 2027.

The commercial logic is clear but distant. Regeneron will lead research and development, while Sanofi will lead global commercial efforts if the candidates succeed. The companies will split development and commercialization costs and future profits equally, preserving the existing Dupixent profit-sharing arrangement.

USD 8.0 billion potential carries risk

The agreement gives Regeneron USD 1.0 billion upfront and up to an additional USD 7.0 billion in development, regulatory and commercial milestones, according to the October 1, 2026 Sanofi release. That creates a potential payment structure of up to USD 8.0 billion, but the most advanced new antibody remains in early clinical development.

That timing matters for Sanofi stock. The company is paying for pipeline optionality before the four new medicines have demonstrated regulatory approval or commercial sales, while the alliance is designed to extend the immunology franchise established by Dupixent. Reuters reported on October 1, 2026, that analysts viewed the deal positively but also highlighted the challenge of building enough pipeline strength to offset Dupixent's patent loss later this decade.

October 30 results set the next test

Sanofi's investor-relations calendar lists October 30, 2026, for third-quarter 2026 results, giving the market a near-term checkpoint for operating performance alongside the longer-term alliance story. The next report can show whether the current business is supporting the investment required for the four early-stage programs.

At Lang & Schwarz, Sanofi stock was trading at EUR 70.23 on October 2, 2026 at 12:31 p.m. CEST, down 3.16 percent versus the Lang & Schwarz prior close of EUR 72.52. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.